Breast Cancer News
>
Dato-DXd Better Than Chemo for TNBC Brain Mets

Dato-DXd Better Than Chemo for TNBC Brain Mets

The treatment may become a new option for people who can’t take Keytruda.
IV Bag 2466x1644

There are limited treatment options for people with triple-negative breast cancer (TNBC) that has spread to the brain (brain metastases). New study results suggest Datroway (chemical name: datopotamab deruxtecan-dlnk), commonly called Dato-DXd, may be an effective treatment for TNBC brain mets.

The research was presented at the European Society for Medical Oncology (ESMO) Congress 2026.

About a third of people with metastatic TNBC will develop brain mets. Since Dato-DXd, an antibody-drug conjugate, is approved to treat unresectable or metastatic TNBC in people who aren’t able to receive Keytruda (chemical name: pembrolizumab), the researchers wanted to know if it worked specifically on brain mets.

An analysis of 61 people with triple-negative breast cancer (TNBC) who had brain metastases in the TROPION-Breast02 study found that Dato-DXd was more effective than the researcher’s choice of chemotherapy.

The researchers looked at both progression-free survival (how long people lived without the cancer growing) and overall survival (how long people lived whether or not the cancer grew) in people receiving Dato-DXd or chemo.

People on Dato-DXd who had brain metastases lived 7.7 months without the cancer growing anywhere in the body, while people receiving chemo lived 3.5 months. People receiving Dato-DXd lived 13.5 months with or without the cancer growing, compared to 10.7 months for people receiving chemo.

Additionally, about 63% of the brain metastases responded in some way to DatoDXd, compared to about 38% of brain metastases that responded to chemo.

The researchers also looked specifically at how long people lived without the brain metastases growing — called central nervous system progression-free survival (CNS PFS). CNS PFS ranged from 6.9 months to 19.3 months for people getting Dato-DXd; for people getting chemo, it was 1.5 to 5.8 months. This was especially interesting because it showed that Dato-DXd specifically worked in the brain.

 

This content is made possible by Lilly.

Was this article helpful?